Physician profile
Daniel Deem
NPI 1487948386
$1,329.65
in general payments reported to CMS, 2019-2025
17 companies · $782 in 2025
The $782 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31.92 · 2021: $46.83 · 2022: $18.84 · 2023: $45.27 · 2024: $405 · 2025: $782.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,232.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $588.55 | 2022-2025 | Repatha, Repatha, Otezla |
| Pfizer INC. | $173.12 | 2024-2025 | |
| Novo Nordisk INC | $129.98 | 2019-2025 | Ozempic, Wegovy |
| Abbvie INC. | $65.85 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $63.59 | 2025 | Farxiga, Airsupra |
| Lilly USA, LLC | $48.56 | 2021-2024 | Jardiance, Zepbound |
| Kowa Pharmaceuticals America, INC. | $35.20 | 2024-2025 | Zoryve |
| Corium, LLC | $32.46 | 2025 | Azstarys |
| Sumitomo Pharma America, INC. | $27.32 | 2025 | Gemtesa |
| Radius Health, INC. | $24.21 | 2025 | Tymlos |
| Merck Sharp & Dohme LLC | $24.02 | 2024 | Gardasil, Gardasil 9, Capvaxive |
| Ironshore Pharmaceuticals INC. | $23.68 | 2024 | |
| Esperion Therapeutics, INC. | $21.96 | 2025 | Nexletol |
| Exact Sciences Corporation | $19.55 | 2024 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $18.53 | 2025 | Eliquis |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.18 | 2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $15.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Deem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.